Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Net Margin: 2020-2025

Historic Net Margin for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to -4,174.62%.

  • Insight Molecular Diagnostics' Net Margin rose 755843.00% to -4,174.62% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,383.33%, marking a year-over-year increase of 476533.00%. This contributed to the annual value of -3,245.14% for FY2024, which is 305046.00% down from last year.
  • Insight Molecular Diagnostics' Net Margin amounted to -4,174.62% in Q3 2025, which was down 121.97% from -1,880.69% recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Net Margin ranged from a high of 1.65% in Q1 2023 and a low of -16,497.81% during Q4 2022.
  • Moreover, its 3-year median value for Net Margin was -2,262.92% (2024), whereas its average is -3,514.04%.
  • As far as peak fluctuations go, Insight Molecular Diagnostics' Net Margin skyrocketed by 6,166,383bps in 2021, and later crashed by 1,549,795bps in 2022.
  • Quarterly analysis of 5 years shows Insight Molecular Diagnostics' Net Margin stood at -999.86% in 2021, then slumped by 1,549,795bps to -16,497.81% in 2022, then skyrocketed by 1,134,526bps to -5,152.55% in 2023, then surged by 288,963bps to -2,262.92% in 2024, then soared by 755,843bps to -4,174.62% in 2025.
  • Its Net Margin was -4,174.62% in Q3 2025, compared to -1,880.69% in Q2 2025 and -312.02% in Q1 2025.